AI drug discovery
-
Technology & Infrastructure · Models & LLMs Insilico Medicine Convenes an Open Consortium For Benchmark Quality in AI-Driven Drug Discovery
Insider Brief PRESS RELEASE — Insilico Medicine (“Insilico”; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the launch of the Open Drug Discovery and Development Consortium (O3DC) – www.o3dc.org, an open… -
Technology & Infrastructure · Models & LLMs SandboxAQ Launches AQPotency for Drug-Target Screening
-
Business & Markets · Enterprise Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
-
Technology & Infrastructure · Models & LLMs Vanderbilt Research Aims to Improve AI Drug Discovery
-
Technology & Infrastructure · Applications & agents FLAIR Debuts CES 2025 Showcasing Cutting-Edge Industrial AI Solutions and Hong Kong’s Innovation Prowess
-
Technology & Infrastructure · Models & LLMs Study Shows AI-Powered Drug Discovery Has Near Perfect Success Rate in Phase I Clinical Trials
The AI economy, every weekday morning
The daily briefing plus the weekly Scale-ups to watch edition. Free, no spam, unsubscribe any time.